Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation.
BACKGROUND
Several genetic polymorphisms increase the risk for venous thrombembolism (VTE). In particular, combined oral contraceptives (COCs) are known to enhance the risk for VTE and are therefore contraindicated.


METHODS
We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. At the time of her first consultation at our clinic, the ultrasound examination showed a complete involution of her venous thrombosis.


CONCLUSIONS
COCs can be used in patients with thrombogenic mutations and anticoagulatory therapy in individual cases.
Ott
Johannes
J
Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University Vienna, Vienna, Austria. johannes.ott@meduniwien.ac.at
Promberger
Regina
R
Kaufmann
Ulrike
U
Huber
Johannes C
JC
Frigo
Peter
P
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010644:Phenprocoumon / Q000627:therapeutic use; D018455:Protein S Deficiency / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D020246:Venous Thrombosis / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics / Q000473:pathology
D000925:Anticoagulants; D003277:Contraceptives, Oral, Combined; D010644:Phenprocoumon